Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.pharmaceutical-technology.com/news/altrubio-secures-225m-funds/
https://www.globenewswire.com/news-release/2024/05/21/2885505/0/en/AltruBio-Secures-up-to-225M-Oversubscribed-Series-B-Financing-to-Advance-the-Clinical-Development-of-Novel-Immune-Checkpoint-Enhancer-Program.html
https://www.globenewswire.com/news-release/2024/05/01/2873180/0/en/AltruBio-to-Participate-in-Upcoming-May-2024-Medical-Conferences.html
https://www.globenewswire.com//news-release/2023/12/07/2792479/0/en/AltruBio-Announces-Enrollment-of-First-Patient-in-Phase-2-Clinical-Program-of-ALTB-268-for-the-Treatment-of-Ulcerative-Colitis.html
https://www.globenewswire.com//news-release/2023/09/26/2749411/0/en/AltruBio-Announces-FDA-Clearance-of-IND-Application-for-Immune-Checkpoint-Enhancer-ALTB-268-to-initiate-a-Phase-2-Clinical-Trial-for-the-Treatment-of-Ulcerative-Colitis.html
https://www.globenewswire.com/news-release/2023/08/01/2715771/0/en/AltruBio-Announces-Positive-Topline-Data-from-Phase-1-Trial-of-Immune-Checkpoint-Enhancer-ALTB-268-for-the-Treatment-of-Ulcerative-Colitis.html
https://www.globenewswire.com/news-release/2023/06/15/2688865/0/en/AltruBio-to-Present-at-the-Federation-of-Clinical-Immunology-Societies-FOCIS-2023-Annual-Meeting.html
https://www.globenewswire.com/news-release/2023/05/31/2679328/0/en/AltruBio-to-Present-at-the-2023-BIO-International-Convention.html
https://www.globenewswire.com/news-release/2023/05/08/2663250/0/en/AltruBio-Announces-Poster-Presentation-at-Digestive-Disease-Week-Conference-2023.html
https://www.globenewswire.com/news-release/2023/03/09/2624050/0/en/AltruBio-Announces-Panels-and-Presentations-at-Three-March-Healthcare-Conferences.html